Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Use of zoledronic acid in the treatment of Paget’s disease

Authors Margaret Seton, Stephen M Krane

Published 15 November 2007 Volume 2007:3(5) Pages 913—918


Margaret Seton1, Stephen M Krane2

1,2Division of Rheumatology, Allergy and Immunology; 2Center for Immunology and Inflammatory Diseases, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, MA, USA

Abstract: This review examines the use of zoledronic acid in the treatment of Paget’s disease of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of oversuppression of bone by the more potent bisphosphonates and their association with avascular necrosis of the jaw are noted.

Keywords: Paget’s disease of bone, bisphosphonates, zoledronic acid

Download Article [PDF]